Agency / Source: Becton, Dickinson and Company

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management - Experience the Difference of Enterprise-wide Medication Management at #ASHP16 Midyear Meeting - BD.com
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management

 

PRZOOM - /newswire/ - Las Vegas, NV, United States, 2016/12/05 - Experience the Difference of Enterprise-wide Medication Management at #ASHP16 Midyear Meeting - BD.com. NYSE: BDX

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BD (Becton, Dickinson and Company), a leading global medical technology company, will demonstrate an enhanced technology platform designed with the ability to synchronize BD medication management technologies, including the company’s leading Pyxis™ and Alaris™ systems, at this year’s American Society of Health-System Pharmacists (ASHP) 2016 Midyear Meeting being held in Las Vegas from Dec. 4-8.

While national data show that approximately 68 percent of medication errors occur during the administration phase, errors can happen during any step of the medication management processi. During last year’s ASHP Midyear Meeting, BD revealed how its strong portfolio of solutions can help improve the safety and cost of healthcare during each step of the process. Since then, BD is continuing its focus on creating a new enterprise medication management platform that will harmonize its advanced technologies to close the communication gaps between devices and help optimize the entire medication management process. This unique approach is coupled with new services, backed by clinical experts that will support a hospital or health system to define, execute and measure its medication management processes and continuously improve workflows and optimize processes.

“BD is a leader in medication management technologies because of our continued commitment to innovation and deep understanding of the customer challenges with medications,” said Ranjeet Banerjee, worldwide president of Medication Management Solutions for BD. “We know it’s not enough to simply have the right technologies in place if they aren’t connected to other parts of the process. BD’s innovation roadmap includes device hardware, interoperability software, data analytics applications and services creating an interconnected system that is designed to help improve outcomes across the continuum of care.”

During ASHP, BD will showcase the medication management processes and illustrate how medication safety and efficiency can be enhanced across the care continuum by combining three key elements to improve customer outcomes:

Medication Management Platform Innovation: From medication reconciliation upon admission, dispensing in the pharmacy and administration at the bedside, BD will showcase leading technologies to help hospitals and health systems manage inventory, prepare IV medications and safely dispense and administer medications along with tracking technologies to know where medications are from the pharmacy to the bedside.
Advanced Data and Analytics: New BD analytics applications can provide recommendations on ways to optimize the medication management system for peak safety and efficiency, which complements EHR data and helps improve workflow and patient safety.

Customer-centric Support and Services: BD is implementing new services that will help hospitals and health systems review and understand its own medication management data and determine opportunities to improve outcomes.

For more information, or to register for any of the BD-sponsored activities at ASHP, please visit us at Booth #821.

About BD
BD (bd.com) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 40,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.

This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding potential future sales and product development. Forward looking statements may be identified by use of words such as “will”,“plan”,“believe”,“expect” or other words of similar meaning. All such statements are based upon the current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. A number of factors could cause actual results to vary materially, including, without limitation, difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; competitive factors including technological advances and new products introduced by competitors; pricing and market pressures; potential cuts in governmental healthcare spending and measures to contain healthcare costs; adverse changes in regional, national or foreign economic conditions; product efficacy or safety concerns; fluctuations in costs and availability of materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws and regulations impacting our business or changes in enforcement practices with respect to such laws; future healthcare reform; as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

I California Hospital Patient Safety Organization (2012, October). Patient Safety News. 4(9).

Contact: Monique N. Dolecki - BD Investor Relations
P: 201 847 5378 - E: monique_dolecki[.]bd.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Becton, Dickinson and Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
BD | ASHP
Contact: Matthew Coppola - BD.com 
201-847-7370 matthew_r_coppola[.]bd.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Becton, Dickinson and Company securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Becton, Dickinson and Company / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen to Present 12 Abstracts At the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress
Imec Announces elPrep5 - the Newest Version of its Software Platform for DNA Analysis
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  RightITnow, Inc.

Visit  JobsWare.com

Visit  BizJobs.com







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today